News Releases
Oct 26 2021
Avid Bioservices to Join S&P SmallCap 600 Index
Oct 14 2021
Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy
Oct 7 2021
Avid Bioservices Appoints Matthew Kwietniak as Chief Commercial Officer
Sep 8 2021
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2021 and Recent Developments
Sep 2 2021
Avid Bioservices to Participate at Upcoming Investor Conferences
Sep 1 2021
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2022 After Market Close on September 8, 2021
Jul 1 2021
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D., to Board of Directors
Jun 29 2021
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
Jun 22 2021
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021
May 25 2021
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)